Pharmaceutical Executive-12-01-2018

Financial leaders from clinical-stage biopharma gather to discuss the critical role of finance and accounting (F&A) in supporting and sustaining the science at the forefront of engagement with investors.

The Commission’s gestures toward enacting formal standards to digitize health records are masking wider policy gaps.

Almost a year and a half later, key understandings have emerged to help companies better combat future data-breach attempts.

While the increasing importance of real-world evidence (RWE) is widely acknowledged, the dramatic shift required by pharma to embed meaningful and holistic benefits from this capability is still a work in progress.

Sonalee Agarwal, head of value and evidence strategy for Alnylam, talks with Pharm Exec about the role of real-world evidence in the rare and ultra-rare disease space.

In pharma, there may be hope that companies' and the industry's ability to adapt to change may finally be catching up to the pace of new and intelligent uses of technology and clinical data.

There is still no structured method of assessing pricing and access risk for drug manufacturers. Presented here is a straightforward measure for integrating pricing and access risk into portfolio planning and decision-making.

Objective considerations when gauging investment.

Click the title above to open the Pharmaceutical December 2018 issue in an interactive PDF format.

With a reputation as a reliable, if somewhat unspectacular, marketplace, Malaysia has long appealed to life science investors lured in by the prospect of generating consistent returns.

Efforts intensify to bring outlays more in line with global trends.